Dipna Pharmachem Ltd
₹ 9.00
3.45%
27 May
4:01 p.m.
About
Incorporated in 2011, Dipna Pharmachem Limited is engaged in the trading and distribution of a wide range of pharmaceutical raw materials including APIs, Excipient, and chemical formulation products across India.[1]
Key Points
- Market Cap ₹ 21.6 Cr.
- Current Price ₹ 9.00
- High / Low ₹ 24.1 / 8.00
- Stock P/E 18.5
- Book Value ₹ 10.0
- Dividend Yield 0.00 %
- ROCE 9.00 %
- ROE 6.97 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.90 times its book value
- Debtor days have improved from 139 to 104 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 9.98%
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|
17 | 20 | 30 | 31 | 73 | 100 | 126 | |
16 | 20 | 30 | 31 | 71 | 98 | 122 | |
Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 |
OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 2 |
Tax % | 14% | 40% | 0% | 60% | 26% | 34% | |
0 | 0 | 0 | 0 | 1 | 1 | 1 | |
EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.47 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 43% |
3 Years: | 49% |
TTM: | 36% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 72% |
3 Years: | 148% |
TTM: | -22% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 14% |
Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0 | 0 | 0 | 0 | 0 | 12 | 12 |
Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 |
5 | 6 | 10 | 12 | 10 | 16 | 18 | |
6 | 8 | 8 | 12 | 24 | 37 | 61 | |
Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 104 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
11 | 14 | 18 | 25 | 36 | 78 | 104 | |
Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 104 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
-3 | -2 | 3 | -21 | |||
0 | 0 | -0 | -0 | |||
3 | 2 | -3 | 26 | |||
Net Cash Flow | 0 | 0 | -0 | 5 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|
Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 |
Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 |
Days Payable | 142 | 148 | 105 | 145 | 123 | 139 |
Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 |
Working Capital Days | 116 | 114 | 119 | 150 | 59 | 126 |
ROCE % | 8% | 5% | 3% | 17% | 9% |
Documents
Announcements
- Board Meeting Outcome for Outcome Of Board Meeting Held On 6Th May, 2024 6 May
- Board Meeting Intimation for Re-Schedule Of Board Meeting Held Today I.E. 2Nd May, 2024 2 May
- Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (LODR) Regulations, 2015 1 May
- Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended On 31St March, 2024 27 Apr
- Submission Of Certificate Under Regulation 40(9) Read With Regulation 40(10) Of SEBI (LODR) Regulations, 2015 For The Financial Year Ended On 31St March, 2024 26 Apr
Business Area[1] Dipna Pharmachem Ltd. (DPL) is engaged in trading and distribution of pharmaceutical raw materials such as APIs (Active Pharmaceutical Ingredients), excipients, and chemical formulation products. Presently its product portfolio comprises 61 AIPs and AIPs intermediates such as Cephalosporins, Cardiovascular, Anti - Bacteria, Quinolones, Veterinary, Anti - Virus, Anti - Inflammatory, Neuropsychiatry, Steroid Hormone, etc.